Nordic Life Science 1
BUSINE S S D E A L DCprime is a Dutch clinical st
age company developing cancer relapse vaccines aimed at reducing tumor recurrence. of the combination is to establish a unified company built on combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology. The company will maintain its corporate headquarters in Stockholm, Sweden, and consolidate research, process development and future manufacturing efforts at the location in Leiden, the Netherlands. Immunicum’s shares will continue to trade on the Nasdaq Stockholm. Payment in the transaction is effectuated through an issue in kind of 73,909,635 new shares in Immunicum, representing 44 percent of the shares in Immunicum on a fully diluted basis. DCprime’s current majority shareholder, Van Herk Investments B.V. will thereby become a significant shareholder of the combined entity and intends to invest up to SEK 82.5 million in the company. Erik Manting, currently CEO of DCprime, will join Immunicum’s leadership team as Chief Business Officer and deputy CEO. Jeroen Rovers, currently Chief Medical Officer at DCprime, will have the role of the Managing Director of DCprime in the combination.